We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva

By LabMedica International staff writers
Posted on 01 Jan 2025
Print article
Image: The LC-MS/MS assay can serve as a reference method to validate emerging biosensors for renal function monitoring (Photo courtesy of 123RF)
Image: The LC-MS/MS assay can serve as a reference method to validate emerging biosensors for renal function monitoring (Photo courtesy of 123RF)

Timely and accurate monitoring of renal function is essential for managing patients at risk of acute kidney injury (AKI), which affects about 12% of hospitalized patients and up to 57% of ICU patients. In approximately 20% of these cases, the condition progresses to more severe stages of AKI, leading to longer hospital stays, higher mortality rates, and an increased need for invasive renal replacement therapies. Early intervention, driven by frequent or continuous monitoring of renal function biomarkers like creatinine, could potentially delay this progression. As renal failure can advance quickly, frequent venipuncture for creatinine testing is required. Recent advances in microfluidic devices and biosensors have led to the exploration of alternative biofluids, such as sweat and saliva, for non-invasive, continuous monitoring of creatinine. Researchers have now developed a novel Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) assay for detecting low creatinine levels in these biofluids.

Researchers at Eindhoven University of Technology (Eindhoven, The Netherlandsl) investigated the correlation between creatinine concentrations in sweat, saliva, and plasma during hemodialysis, with an eye toward future biosensor applications. They measured creatinine levels in sweat, saliva, and plasma from 40 patients undergoing hemodialysis. Using the novel LC-MS/MS assay, they quantified low creatinine concentrations in these biofluids. Correlation analyses were conducted to compare creatinine levels across the biofluids. The LC-MS/MS assay demonstrated excellent accuracy (93.9% to 97.8%) and low imprecision (3.4% to 8.1%) for measuring very low creatinine concentrations, with a limit of quantitation of 1.26 µmol/L.

The study revealed strong correlations between creatinine concentrations in sweat and saliva compared to plasma (ρ: 0.68 and 0.80, respectively). During hemodialysis, creatinine concentrations declined similarly across all three biofluids. These strong correlations suggest that sweat and saliva could serve as reliable, non-invasive alternatives to traditional blood tests for assessing kidney function. This research improves the understanding of creatinine excretion pathways and lays the groundwork for the development of patient-friendly, continuous kidney function monitoring methods, such as wearable biosensors.

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.